PERTH, Australia – The pharma industry largely supports the Therapeutic Goods Administration's (TGA) update to its orphan drug regulations, expected to become effective July 1, though industry stakeholders offered some suggestions for modifications, mostly regarding eligibility criteria for orphan designation and the time lapse for the validity period.
PERTH, Australia – The pharma industry largely supports the Therapeutic Goods Administration's (TGA) update to its orphan drug regulations, expected to become effective July 1, though industry stakeholders offered some suggestions for modifications, mostly regarding eligibility criteria for orphan designation and the time lapse for the validity period.
PERTH, Australia – Australia will save nearly A$500 million (US$379 million) over the next four years due to a deal hammered out by the federal government and pharmaceutical industry stakeholders.
PERTH, Australia – Australia will save nearly A$500 million (US$379 million) over the next four years due to a deal hammered out by the federal government and pharmaceutical industry stakeholders.
PERTH, Australia – Melbourne-based Opthea Ltd.'s recent A$45 million (US$33.7 million) equity financing will go toward expanding clinical development of its VEGF-C/D trap therapy candidate, OPT-302, for wet age-related macular degeneration (AMD) and diabetic macular edema (DME), aiming to prove additive benefit to existing VEGF-A treatments.
PERTH, Australia – Melbourne-based Opthea Ltd.'s recent A$45 million (US$33.7 million) equity financing will go toward expanding clinical development of its VEGF-C/D trap therapy candidate, OPT-302, for wet age-related macular degeneration (AMD) and diabetic macular edema (DME), aiming to prove additive benefit to existing VEGF-A treatments.
An Australian Senate committee recommended last week that Parliament pass the Therapeutic Goods Amendment Bill (2016 Measures No. 1) that would overhaul drug and device regulations to speed access to novel therapies and reduce regulatory red tape.
